Research map: Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study · 2026 · Related
  3. Breast cancer · Nadia Harbeck · 2019 · 3072 citations · Cited by this paper
  4. Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review · 2026 · Related
  5. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas · Azael Freites‐Martínez · 2020 · 900 citations · Cited by this paper
  6. Successful remdesivir treatment of coronavirus OC43 pneumonia in a lung transplant recipient · 2025 · Related
  7. Non–Small Cell Lung Cancer, Version 4.2024 · Gregory J. Riely · 2024 · 841 citations · Cited by this paper
  8. A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer · 2025 · Related
  9. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial · Hope S. Rugo · 2023 · 476 citations · Cited by this paper
  10. A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study · 2026 · Related
  11. Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications · Anna Shvartsur · 2014 · 410 citations · Cited by this paper
  12. Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease · 2025 · Related
  13. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study · Myung‐Ju Ahn · 2024 · 228 citations · Cited by this paper
  14. The role of gut microbiome in chemoresistance property development in colorectal cancer tissue and its novel therapeutic strategies · 2026 · Related
  15. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 · Aditya Bardia · 2024 · 187 citations · Cited by this paper
  16. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study · 2025 · Related
  17. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression · Aditya Bardia · 2024 · 179 citations · Cited by this paper
  18. Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel · 2025 · Related
  19. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors · Qing Wei · 2024 · 165 citations · Cited by this paper
  20. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study · Luis G Paz-Ares · 2024 · 132 citations · Cited by this paper
  21. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer · Xinlin Liu · 2022 · 125 citations · Cited by this paper
  22. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response · Hannah L. Chang · 2023 · 115 citations · Cited by this paper
  23. Targeting Trop-2 in cancer: Recent research progress and clinical application · Shuying Qiu · 2023 · 102 citations · Cited by this paper
  24. Trop2-targeted therapies in solid tumors: advances and future directions · Xinlin Liu · 2024 · 83 citations · Cited by this paper
  25. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan · Rebecca Suk Heist · 2024 · 75 citations · Cited by this paper
  26. Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC · Wenfeng Fang · 2025 · 71 citations · Cited by this paper
  27. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors · Blessie Elizabeth Nelson · 2023 · 63 citations · Cited by this paper
  28. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer · Rebecca Alexandra Dent · 2023 · 58 citations · Cited by this paper
  29. Antibody–drug conjugates: prospects for the next generation · Meriem Grairi · 2024 · 54 citations · Cited by this paper
  30. Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review · Huan Jie · 2025 · 51 citations · Cited by this paper
  31. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies · Puguang Yu · 2024 · 44 citations · Cited by this paper
  32. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial · Wen‐Feng Fang · 2025 · 44 citations · Cited by this paper
  33. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation · Solange Peters · 2024 · 37 citations · Cited by this paper
  34. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer · Taihang Shao · 2022 · 34 citations · Cited by this paper
  35. LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial · Rebecca Alexandra Dent · 2025 · 30 citations · Cited by this paper
  36. Targeting Trop2 in solid tumors: a look into structures and novel epitopes · Xinlin Liu · 2023 · 27 citations · Cited by this paper
  37. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies · Quchang Ouyang · 2025 · 27 citations · Cited by this paper
  38. Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives · Xianglong Shi · 2025 · 24 citations · Cited by this paper
  39. Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook · Yongshun Liu · 2024 · 20 citations · Cited by this paper

Source: OpenAlex (CC0)